Medtronic to buy SPR Therapeutics for $650 million
Medtronic agreed to acquire SPR Therapeutics for $650 million, adding a temporary peripheral nerve stimulation therapy for chronic pain.[1]
Medtronic said the purchase will broaden its pain-treatment offerings and is expected to close later this year, subject to regulatory approvals.[1]
SPR's 60-day Sprint system has treated about 6,100 patients, and a retrospective review found more than 71% reported significant pain relief.[1]
This is Medtronic's third major deal in five months, following its $550 million purchase of Scientia Vascular in March and a $585 million acquisition of CathWorks in February.[1]
Show source details & analysis (1 source)
📌 Key Facts
- Medtronic agreed to acquire SPR Therapeutics for $650 million, adding a temporary peripheral nerve stimulation therapy for chronic pain.
- SPR’s 60‑day Sprint system has treated about 6,100 patients, with more than 71% reporting significant pain relief in a retrospective review.
- This is Medtronic’s third major deal in five months, after a $550 million Scientia Vascular acquisition in March 2026 and a $585 million CathWorks deal in February 2026, with closing of the SPR purchase expected later this year pending regulatory approvals.
📰 Source Timeline (1)
Follow how coverage of this story developed over time
May 20, 2026